Antengene Corporation is a technology company.
Antengene Corporation has raised $238.0M across 3 funding rounds.
Antengene Corporation has raised $238.0M in total across 3 funding rounds.
Antengene Corporation has raised $238.0M in total across 3 funding rounds.
Antengene Corporation's investors include Qiming Venture Partners.
Antengene Corporation is a biopharmaceutical company specializing in innovative oncology medicines, focusing on discovering, developing, and commercializing first-in-class and best-in-class cancer therapies primarily for patients in China, the Asia Pacific region, and globally[1][2]. Its product pipeline includes 12 clinical and pre-clinical assets targeting hematologic malignancies and solid tumors, with key therapies like ATG-010 (selinexor), a selective inhibitor of nuclear export that induces cancer cell apoptosis[2][4]. Antengene serves cancer patients and healthcare providers by addressing significant unmet medical needs through novel mechanisms of action (MoAs), showing strong growth momentum with multiple ongoing cross-regional clinical trials and recent listing on the Hong Kong Stock Exchange[2].
Founded in April 2017 by Dr. Jay Mei, who serves as Chairman and CEO, Antengene emerged from a vision to "Treat Patients Beyond Borders" by integrating drug discovery and clinical development with a global footprint anchored in Asia Pacific[2]. The company quickly gained traction by building a robust pipeline and securing nine Investigational New Drug (IND) approvals, reflecting its rapid evolution from a clinical-stage biotech startup to a commercial-stage global player in cancer therapeutics[2][3].
Antengene rides the trend of precision oncology and targeted cancer therapies, leveraging advances in molecular biology and immuno-oncology to develop therapies that address resistance mechanisms and tumor heterogeneity[2][4]. The timing is critical as cancer remains a leading cause of death globally, and there is increasing demand for innovative treatments that improve survival and quality of life. Market forces such as rising cancer incidence in Asia Pacific, regulatory support for novel therapies, and growing investment in biotech innovation favor Antengene’s growth. The company influences the broader ecosystem by advancing Asia Pacific’s role in global biopharmaceutical R&D and fostering cross-border clinical collaborations[2][4].
Antengene is poised for continued expansion as it advances its pipeline through late-stage clinical trials and commercial launches, particularly in Asia Pacific markets. Future trends shaping its journey include the rise of combination therapies, immuno-oncology, and personalized medicine. Its influence may grow by setting new standards for cancer treatment accessibility and innovation in emerging markets. With a strong leadership team and strategic global partnerships, Antengene is well-positioned to become a leading oncology biotech company with a lasting impact on cancer care worldwide[2][4].
Antengene Corporation has raised $238.0M across 3 funding rounds. Most recently, it raised $97.0M Series C in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $97.0M Series C | Qiming Venture Partners | |
| Jan 1, 2019 | $120.0M Series B | Qiming Venture Partners | |
| Aug 1, 2017 | $21.0M Series A | Qiming Venture Partners |